April 8, 2013

Asiatic Health NewsClinical trial:A randomized controlled cross-over study of Flupenthixol + Melitracen in Functional Dyspepsia.BACKGROUND:Functional dyspepsia is a prevalent condition associated with diminished quality of life (QoL) and high economic burden.

AIM:To study the efficacy of a combination of Flupenthixol and Melitracen (F+M) with anxiolytic and antidepressant properties in functional dyspepsia using a randomized controlled cross-over design.

RESULTS: Twenty-five patients (14 females, 11 males; mean age = 34.3 +/- 9.9 years) were enrolled and 24 completed the 8-week study. There was a significant improvement in subjective global symptom relief with Flupenthixol + Melitracen vs. placebo (ITT: 73.9% vs. 26.1%, P = 0.001). No difference was noted whether the initial treatment was Flupenthixol + Melitracen or placebo. No significant side effects were noted.

CONCLUSIONS:A combination of Flupenthixol and Melitracen is safe and effective in the short-term treatment of functional dyspepsia. Flupenthixol + Melitracen is associated with significant improvement in Quality of Life independent of the presence of Anxiety & Depression.

Ref

: 1. A

limen

t Pha

rmac

ol T

her.

2008

Jun

1;2

7 (1

1): 1

148-

55.

Flupentixol BP 0.5 mg + Melitracen INN 10 mgA new dimension for treating Anxiety and Depression

ITT=Intent to treat

Courtesy By Now available in Alu-Alu Blister

74%26%

Antison(Flupenthixol + Melitracen)

Placbo

Functional Dyspepsia